- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06117163
Integrated Mental Health Care for Pregnant Women With HIV in Kenya: The Tunawiri Study
May 7, 2024 updated by: University of Colorado, Denver
Integration of a Collaborative Care Model for Mental Health Services Into HIV Care for Pregnant and Postpartum Women in Kenya (the Tunawiri Study)
This study seeks to improve mental health, pregnancy, and HIV outcomes among pregnant and postpartum women living with HIV with common mental health disorders in Kenya.
The investigators will tailor a collaborative care model for peripartum women with HIV experiencing mental health symptoms and evaluate its impact on participants' mental health, antenatal, and HIV care outcomes.
The investigators will actively engage key stakeholders throughout the process and assess scalability and sustainability through multi-method approaches.
This study will contribute to the overall goal of achieving optimal health outcomes for women living with HIV and their families in sub-Saharan Africa.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Common mental disorders (CMD) of depression and anxiety are prevalent and largely untreated among Kenyan pregnant and postpartum women living with HIV (PPWH).
CMD lead to poor maternal and child health outcomes and contribute to lack of HIV care engagement and virologic failure in PPWH.
While efficacious treatments for CMD exist, scaling treatment within routine health care in low- and middle-income (LMIC) settings will require stakeholder engagement and both effectiveness and implementation data to inform scale up and sustainability.
The study team has integrated other efficacious interventions into antenatal (ANC) and HIV care in Kenya.
The investigators now propose to integrate proven mental health services using a collaborative care model, combined with a low intensity evidence-based intervention (problem solving therapy), while targeting known social determinants of HIV-related health for PPWH (stigma and IPV).
Building on the current multidisciplinary approach for HIV care in Kenya, the proposed Collaborative Care Model (CCM) will utilize existing peer mentor mothers, non-specialist behavioral care managers, and psychiatric nurses; and will incorporate a consultant psychiatrist into the ANC/HIV care team.
Guided by the EPIS (Exploration-Preparation-Implementation-Sustainment) framework, the overall study goal is to integrate collaborative care for perinatal CMD within routine ANC/HIV services in Kenya, assess the costs and cost-effectiveness of this approach, and work with policy and decision makers to determine key considerations for scale-up.
Specifically, in Aim 1, the investigators will identify contextual barriers and facilitators to refine an optimal integration model for delivering collaborative care model using multimethod data collection (focus groups with providers, in-depth interviews with key informants, and a clinic readiness checklist).
A workshop with the study Advisory Board comprising of both county and national level stakeholders, will allow investigators to translate findings into a locally relevant CCM.
In Aim 2, the investigators will test CCM in antenatal care for PPWH in a hybrid type 2 implementation-effectiveness trial using a stepped wedge design at 15 primary health care facilities in southwestern Kenya.
The investigators will introduce CCM care for PPWH diagnosed with CMD during antenatal care.
The co-primary health outcomes at 12 months postpartum will be (1) recovery from depression or anxiety symptoms in PPWH, and (2) proportion PPWH with sustained viral suppression and retention in HIV care.
Key implementation outcomes are feasibility and acceptability.
Finally, in Aim 3, the investigators will refine CCM implementation strategies through cost-effectiveness and dissemination research.
The investigators will carry out costing and cost-effectiveness analysis and invite policy and decision-makers to participate in a nominal group technique process to elucidate factors for further scale up and sustainment of the CCM approach.
Findings from this study will guide the development of a scalable model adaptable to other LMIC settings, contributing to global HIV and maternal health goals while addressing the burden of untreated CMD.
Study Type
Interventional
Enrollment (Estimated)
900
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lisa Abuogi, MD,MSc
- Phone Number: 303-724-9383
- Email: lisa.abuogi@cuanschutz.edu
Study Locations
-
-
-
Nairobi, Kenya
- Kenya Medical Research Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- pregnant woman living with HIV attending an antenatal clinic in southwestern Kenya
- screening positive for probable common mental disorders
- living in catchment area of study facility.
- on/initiating ART
- >15 years of age
Exclusion Criteria:
- imminent plans of suicide
- severe impairment due to severe mental, neurological or substance use disorders.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Collaborative Care Model (CCM)
The investigators propose a CCM called Tunawiri, meaning "thrive" in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics.
CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication.
|
The investigators propose a CCM called Tunawiri, meaning "thrive" in Kiswahili, that will be integrated within an existing multidisciplinary team of clinicians, mentor mothers, and other clinic staff in Kenyan antenatal care clinics.
CCM includes: 1) clinic-level sensitization and integration, 2) Screening for CMD including anxiety, depression, and trauma symptoms, 3) Problem-solving type cognitive behavioral therapy delivered by lay health workers, 4) Decision Support and monitoring via an Electronic Health Registry, and 5) Psychiatrist case review and nurse-managed mental health medication.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recovery of women from depression
Time Frame: Baseline, 6 months postpartum, 12 months postpartum
|
Depression score is calculated and severity assessed through a survey utilizing the Patient Health Questionnaire Depression Scale (PHQ-9).
PHQ-9 score is obtained by adding a score for each question (total points).
A total score of 0-4 suggests none to minimal depression severity, a score of 5-9 mild depression severity, a score of 10-19 moderate depression severity, and a score of 20-27 severe depression.
Recovery from depression of pregnant and postpartum women living with HIV will be assessed as the change of a total PHQ-9 score from >10 points to equal or less 10 points between baseline and 12 months postpartum.
|
Baseline, 6 months postpartum, 12 months postpartum
|
Recovery of women from anxiety
Time Frame: Baseline, 6 months postpartum, 12 months postpartum
|
Anxiety score is calculated and severity assessed through a survey utilizing the Generalized Anxiety Disorder 7-item (GAD-7).
GAD-7 score is obtained by adding a score for each question (total points).
A total score of 0-4 suggests none to minimal anxiety severity, a score of 5-9 mild anxiety severity, a score of 10-14 moderate anxiety severity, and a score of 15-21 severe anxiety.
Recovery from the anxiety of pregnant and postpartum women living with HIV will be assessed as the change of a total GAD-7 score from >10 points to equal or less 10 points between baseline and 12 months postpartum.
|
Baseline, 6 months postpartum, 12 months postpartum
|
Change in the proportion of women with combined retention and treatment success outcome
Time Frame: Baseline, 6 months postpartum, 12 months postpartum
|
The change in the proportion of women with the combined outcome of HIV care retention (didn't miss any HIV care appointment by 14 or more days) and a suppressed HIV RNA (<400 copies/ml) among pregnant and postpartum women living with HIV assessed through medical records between baseline, 6 months postpartum, and 12 months postpartum.
|
Baseline, 6 months postpartum, 12 months postpartum
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Infant weight at birth
Time Frame: Birth
|
A birth weight, measured in grams, and based on medical records, and categorized into normal weight (equal or more than 2500 grams at birth), low birth weight (<2500 grams at birth), very low birth weight (<1,500 grams at birth), and extremely low birth weight (<1,000 grams at birth).
|
Birth
|
Proportion of women with preterm delivery of women who experienced adverse pregnancy outcomes
Time Frame: Birth
|
The proportion of women who experienced a preterm delivery, measured as delivery <37 weeks of pregnancy) based on medical records.
|
Birth
|
Result of infant HIV test
Time Frame: Birth, 6 weeks, 6 months, 12 months
|
Result of infant HIV test at birth, 6 weeks, 6 months, and 12 months, assessed through medical records and categorized into HIV positive or HIV negative.
|
Birth, 6 weeks, 6 months, 12 months
|
Infant retention in care
Time Frame: Birth, 6 weeks, 6 months, 12 months
|
Continuous visit adherence from birth through 12 months after birth (no missed clinic/pharmacy visit >14 days) assessed through medical records.
|
Birth, 6 weeks, 6 months, 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Lisa Abuogi, MD, MSc, University of Colorado, Denver
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2024
Primary Completion (Estimated)
July 31, 2027
Study Completion (Estimated)
May 31, 2028
Study Registration Dates
First Submitted
October 30, 2023
First Submitted That Met QC Criteria
October 30, 2023
First Posted (Actual)
November 3, 2023
Study Record Updates
Last Update Posted (Actual)
May 8, 2024
Last Update Submitted That Met QC Criteria
May 7, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Keywords
- Mental Health
- Stigma
- Problem Solving Therapy
- Retention in care
- Infant Health
- Linkage to care
- HIV transmission
- Vertical transmission
- Early infant diagnosis
- Antiretroviral therapy adherence
- Prevention of Mother to Child Transmission
- Maternal CD4/viral loads
- Acceptability of interventions
- The Collaborative Care Model
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Mental Disorders
- Acquired Immunodeficiency Syndrome
Other Study ID Numbers
- 23-0498
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Immunodeficiency Virus
-
Merck Sharp & Dohme LLCWithdrawnHIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States
-
National Institute of Allergy and Infectious Diseases...CompletedHuman Immunodeficiency Virus (HIV) | Human Immunodeficiency Virus PreventionUnited States
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
EMD SeronoCompletedHuman Immunodeficiency Virus Infections | Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus | Infections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
bioLytical LaboratoriesNot yet recruitingHuman Immunodeficiency Virus I Infection | Human Immunodeficiency Virus II Infection
-
AbbottCompletedHuman Immunodeficiency Virus InfectionsUnited States, Australia, Belgium, Canada, Czech Republic, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Puerto Rico, Russian Federation, Singapore, Spain, Switzerland, Taiwan, United Kingdom
-
Janssen R&D IrelandCompletedHuman Immunodeficiency Virus Type 1United States, France, United Kingdom, Belgium, Spain, Switzerland, Sweden, Canada, Puerto Rico, Poland
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
Clinical Trials on Collaborative Care Model
-
Chulalongkorn UniversityamfAR, The Foundation for AIDS ResearchCompleted
-
McMaster UniversityUnknown
-
VA Office of Research and DevelopmentNational Institute of Mental Health (NIMH); University of California, Los AngelesCompletedSchizophrenia | Weight Gain | Chronic Illness | Psychotic DisorderUnited States
-
Massachusetts General HospitalActive, not recruitingType 1 Diabetes | Type 2 DiabetesUnited States
-
US Department of Veterans AffairsCompletedDepression | Stress Disorders, PosttraumaticUnited States
-
Trillium Health CentreCentre for Addiction and Mental Health; Medical Psychiatry AllianceCompletedDepression | AnxietyCanada
-
Duke-NUS Graduate Medical SchoolMinistry of Health, Singapore; The Tsao FoundationUnknownCognitive Impairment | DementiaSingapore
-
US Department of Veterans AffairsCompletedMyocardial Ischemia | Coronary Disease | Angina PectorisUnited States
-
University of MichiganCompletedDepression | Bipolar DisorderUnited States
-
University of Texas Southwestern Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedHypertension | Diabetes | Type 2 Diabetes | Chronic Kidney Disease | High BPUnited States